Skip to main content

CTI BioPharma Corp. (CTIC)

NASDAQ: CTIC · IEX Real-Time Price · USD
2.65
-0.02 (-0.75%)
After-hours:Oct 25, 2021 7:56 PM EDT
2.67
0.00 (0.00%)
At close: Oct 25, 4:00 PM
Market Cap248.21M
Revenue (ttm)n/a
Net Income (ttm)-63.21M
Shares Out92.34M
EPS (ttm)-0.80
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume530,477
Open2.67
Previous Close2.67
Day's Range2.65 - 2.69
52-Week Range2.15 - 4.13
Beta0.76
AnalystsStrong Buy
Price Target7.28 (+172.7%)
Est. Earnings DateNov 9, 2021

About CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was former...

IndustryBiotechnology
IPO DateMar 21, 1997
CEOAdam Craig
Employees22
Stock ExchangeNASDAQ
Ticker SymbolCTIC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CTI BioPharma stock is "Strong Buy." The 12-month stock price forecast is 7.28, which is an increase of 172.66% from the latest price.

Price Target
$7.28
(172.66% upside)
Analyst Consensus: Strong Buy

News

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE, Oct. 14, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award ...

1 week ago - PRNewsWire

CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study

CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.

2 weeks ago - Zacks Investment Research

CTI BioPharma's COVID-19 Candidate Misses Primary Endpoint Mark In Phase 2 Trial

CTI BioPharma Corp (NASDAQ: CTIC) has announced topline results from the PRE-VENT trial of pacritinib in hospitalized COVID-19 patients. The final PRE-VENT analysis was conducted following the randomiza...

3 weeks ago - Benzinga

CTI BioPharma Announces Topline Data from Final Analysis of the PRE-VENT Clinical Trial Evaluating Pacritinib as a Tr...

SEATTLE, Oct. 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced topline results from the PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19...

3 weeks ago - PRNewsWire

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE, Sept. 28, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards t...

3 weeks ago - PRNewsWire

5 Penny Stocks To Watch For September With Upcoming Events

These penny stocks could be in focus as we turn the page on a new month. The post 5 Penny Stocks To Watch For September With Upcoming Events appeared first on Penny Stocks to Buy, Picks, News and Inform...

Other symbols:BLUOBSVPIRS
1 month ago - PennyStocks

CTI BioPharma and DRI Healthcare Trust Announce up to $135 Million Debt and Royalty Transaction

SEATTLE and TORONTO, Aug. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) (CTI) and DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (DRI) today announced transactions totaling up to $135 mil...

2 months ago - PRNewsWire

CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors

SEATTLE, Aug. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematolo...

2 months ago - PRNewsWire

CTI BioPharma Reports Second Quarter 2021 Financial Results

SEATTLE, Aug. 5, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter ended June 30, 2021. "This past quarter, we continued to advance pacr...

2 months ago - PRNewsWire

CTI BioPharma to Report Second Quarter 2021 Financial Results on August 5, 2021

SEATTLE, July 29, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2021 financial results on Thursday, August 5,...

2 months ago - PRNewsWire

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE, July 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to...

2 months ago - PRNewsWire

7 Reddit Penny Stocks to Buy if You Have $100 to Spare

Reddit penny stocks are full of risk and reward, which is why $100 won't hurt you, but it can reward you handsomely. The post 7 Reddit Penny Stocks to Buy if You Have $100 to Spare appeared first on Inv...

4 months ago - InvestorPlace

CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Wednesday, June 16

SEATTLE, June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:30 p.m. ET....

4 months ago - PRNewsWire

CTI BioPharma Reports First Quarter 2021 Financial Results

SEATTLE, June 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2021. "The U.S. Food and Drug Administration's (FDA) a...

4 months ago - PRNewsWire

CTI BioPharma Shares Shoot Higher as FDA Accepts Pacritinib Review Application In Bone Marrow Cancer

The FDA has accepted for review CTI BioPharma Corp's (NASDAQ: CTIC) marketing application seeking approval for pacritinib in myelofibrosis patients with severe thrombocytopenia (low platelet count). Und...

4 months ago - Benzinga

CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with M...

SEATTLE, June 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pacritinib as a ...

4 months ago - PRNewsWire

7 Reddit Penny Stocks Promising to Cure Cancer

These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on I...

5 months ago - InvestorPlace

CTI BioPharma to Report First Quarter 2021 Financial Results on June 1, 2021

SEATTLE, May 5, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2021 financial results on Tuesday, June 1, 2021,...

5 months ago - PRNewsWire

7 Penny Stocks That May Not Be Penny Stocks For Long

Many penny stocks are destined for bankruptcy, but there are some that will survive. Wall Street thinks these companies are undervalued.

6 months ago - InvestorPlace

CTI BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, Apr. 14

SEATTLE, April 7, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 20th Annual Needham Virtual Healthcare Conference at 3:...

6 months ago - PRNewsWire

Why CTI BioPharma's Stock is Down During Today's Session

CTI BioPharma's (NASDAQ:CTIC) stock has been falling Thursday, down 13.06% to a price of $2.55. Thursday the stock has been traded at a volume of 2.13 million, about 326.0% of its recent 30-day volume a...

6 months ago - Benzinga

CTI BioPharma Corp. Announces Pricing of its Public Offering of Common Stock and Preferred Stock

SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies ...

6 months ago - PRNewsWire

CTI BioPharma Corp. Announces Proposed Public Offering of Common Stock and Preferred Stock

SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies ...

6 months ago - PRNewsWire

CTI BioPharma Stock Is Trading Higher On Complete Submission For Rolling Pacritinib US Application

CTI BioPharma Corp (NASDAQ: CTIC) has completed a rolling marketing application submission to the FDA seeking approval of pacritinib for myelofibrosis patients with severe thrombocytopenia (platelet cou...

6 months ago - Benzinga

CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosi...

SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has completed a rolling New Drug Application ("NDA") submission to the U.S. Food and Drug Administratio...

6 months ago - PRNewsWire